Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis. Mark Socinski, MD: Martin, we have seen ...

ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...

Abbreviations: CCOP, Community Clinical Oncology Program; NCI, National Cancer Institute; NSCLC, non–small-cell lung cancer; QOL, quality of life; SD, standard deviation; VA, Veterans Affairs. On the ...

Chemoimmunotherapy extended PFS compared with chemotherapy for patients with extensive-stage small cell lung cancer and ECOG performance status of 2 or 3, according to retrospective study results. The ...

Retrospective analysis among 1418 patients with haematologic malignancies seen at Dana-Farber Cancer Institute between 2007 and 2014. We analysed physician–patient agreement of Eastern Cooperative ...

Doctor talking to older patient Patients with poor performance status have been excluded from pivotal trials on metastatic renal cell carcinoma. In patients with poor performance status and metastatic ...

We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer. The response rate ...